Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is well-positioned to succeed as it approaches the launch of its proprietary psilocybin formulation, COMP360, which addresses the significant unmet need for treatment-resistant depression (TRD). The company is experiencing strong prescriber intent and has initiated the rolling submission of its new drug application (NDA), with a commercially favorable expected label and a manageable REMS process. COMPASS's other mental health indications, such as PTSD and anorexia nervosa, are also progressing towards potential future market opportunities, providing additional potential upside for the company's growth. Financially, COMPASS has a strong cash position and a well-built launch base for COMP360, positioning it for potential success upon FDA approval.

Bears say

Compass Pathways is operating in a relatively new and emerging market, which brings a high level of uncertainty and risk. Their success is heavily dependent on the results of their ongoing clinical trials, which could have a significant impact on their financial performance. Additionally, while there may be potential for expansion into other indications, it is still uncertain and could pose a risk if their treatments are not successful in these areas. It is important for investors to carefully consider these risks before investing in Compass Pathways.

COMPASS Pathways (CMPS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 12 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.